Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model

[1]  M. Biel,et al.  Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma , 2021, Head & neck.

[2]  M. Biel,et al.  A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma , 2021, International Journal of Clinical Oncology.

[3]  P. Choyke,et al.  Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials , 2021, EBioMedicine.

[4]  J. Schiller,et al.  Virus-Like Particle–Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens , 2021, Cancer Immunology Research.

[5]  E. Calvo,et al.  Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[6]  Xiaoxue Xu,et al.  Near Infrared Light Triggered Photo/Immuno-Therapy Toward Cancers , 2020, Frontiers in Bioengineering and Biotechnology.

[7]  S. Gollnick,et al.  Photodynamic Therapy and Immunity: An Update , 2020, Photochemistry and photobiology.

[8]  P. Choyke,et al.  Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models , 2020, Cancer Immunology Research.

[9]  O. Kepp,et al.  Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death , 2020, Oncoimmunology.

[10]  S. Barry,et al.  Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery , 2019, Journal of Immunotherapy for Cancer.

[11]  T. Hasan,et al.  Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease , 2019, Cancers.

[12]  P. van Endert,et al.  Contribution of annexin A1 to anticancer immunosurveillance , 2019, Oncoimmunology.

[13]  P. Choyke,et al.  Near-Infrared Photoimmunotherapy of Cancer , 2019, Accounts of chemical research.

[14]  R. V. van Lier,et al.  Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC , 2018, Front. Immunol..

[15]  P. Choyke,et al.  Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy , 2018, ACS central science.

[16]  Huiyang Zhou,et al.  Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments , 2018, PloS one.

[17]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[18]  Ö. Türeci,et al.  Personalized vaccines for cancer immunotherapy , 2018, Science.

[19]  F. Mami-Chouaib,et al.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy , 2018, Front. Immunol..

[20]  G. Coukos,et al.  Mechanisms regulating T-cell infiltration and activity in solid tumors. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[22]  E. King,et al.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer , 2017, Nature Immunology.

[23]  P. Greenberg,et al.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. , 2017, Cancer cell.

[24]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[25]  Peter L. Choyke,et al.  Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity , 2017, Oncotarget.

[26]  Simon J. Dovedi,et al.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery , 2016, Cancer Immunology Research.

[27]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[28]  U. Demkow,et al.  Immunological aspects of antitumor photodynamic therapy outcome , 2016, Central-European journal of immunology.

[29]  S. V. Van Gool,et al.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines , 2016, Front. Immunol..

[30]  L. Zitvogel,et al.  Natural and therapy-induced immunosurveillance in breast cancer , 2015, Nature Medicine.

[31]  L. Galluzzi,et al.  Combinatorial Strategies for the Induction of Immunogenic Cell Death , 2015, Front. Immunol..

[32]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[33]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[34]  Yukihiko Hiroshima,et al.  Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer , 2015, PloS one.

[35]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[36]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[37]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[38]  P. Choyke,et al.  Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy , 2012, BMC Cancer.

[39]  Abhishek D. Garg,et al.  Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin , 2012, Cancer Immunology, Immunotherapy.

[40]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[41]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[42]  L. Zitvogel,et al.  Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway , 2010, Clinical Cancer Research.

[43]  P. Agostinis,et al.  Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity , 2010, Apoptosis.

[44]  S. Gollnick,et al.  Enhancement of anti-tumor immunity by photodynamic therapy , 2010, Immunologic research.

[45]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[46]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[47]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[48]  P. Mróz,et al.  Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells , 2004, Clinical Cancer Research.

[49]  D. Nixon,et al.  Human CD4+ CD25+ Regulatory T Cells Control T-Cell Responses to Human Immunodeficiency Virus and Cytomegalovirus Antigens , 2004, Journal of Virology.

[50]  G. V. van Dongen,et al.  Photosensitizer-antibody conjugates for detection and therapy of cancer. , 2004, Advanced drug delivery reviews.

[51]  N. Bhardwaj,et al.  Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells1 , 2001, The Journal of Immunology.

[52]  Michael R Hamblin,et al.  Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. , 2001, Cancer research.

[53]  R. Issels,et al.  The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors , 2001, European journal of immunology.

[54]  J. Krosl,et al.  The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. , 1996, Cancer research.

[55]  T. Hasan,et al.  Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. , 1994, British Journal of Cancer.

[56]  J. Levy,et al.  Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. , 1991, Journal of the National Cancer Institute.

[57]  M W Berns,et al.  Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. , 1985, Cancer research.

[58]  J. Levy,et al.  Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. , 1983, Journal of immunology.